What was the market valuation of the antibody drug-discovery market in 2024?

The market valuation was $541.02 Million in 2024. Read More

What is the projected market valuation for the antibody drug-discovery market by 2035?

The projected valuation for 2035 is $1383.21 Million. Read More

What is the expected CAGR for the antibody drug-discovery market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period is 8.91%. Read More

Which companies are considered key players in the antibody drug-discovery market?

Key players include Roche, AbbVie, Amgen, Johnson & Johnson, Merck & Co., Novartis, Bristol-Myers Squibb, GSK, and Sanofi. Read More

What are the main types of antibodies in the market, and what were their valuations in 2024?

In 2024, Monoclonal Antibodies were valued at $216.41 Million, Polyclonal Antibodies at $108.2 Million, Antibody-Drug Conjugates at $108.2 Million, and Bispecific Antibodies at $108.2 Million. Read More

What technologies are driving the antibody drug-discovery market, and what were their valuations in 2024?

In 2024, Hybridoma Technology was valued at $162.31 Million, while Recombinant DNA Technology, Phage Display Technology, and Transgenic Technology were each valued at $108.21 Million. Read More

What therapeutic applications are being targeted in the antibody drug-discovery market, and what were their valuations in 2024?

Therapeutic Applications were valued at $216.41 Million, Diagnostic Applications at $108.21 Million, and Research Applications at $216.4 Million in 2024. Read More

What are the end-use segments in the antibody drug-discovery market, and what were their valuations in 2024?

In 2024, Pharmaceutical Companies were valued at $216.41 Million, Biotechnology Companies at $162.3 Million, and Research Institutions at $162.31 Million. Read More

How does the antibody drug-discovery market in South America compare to other regions?

While specific comparisons are not provided, the growth trajectory suggests a robust development in South America, particularly with a projected valuation increase to $1383.21 Million by 2035. Read More

What factors are contributing to the growth of the antibody drug-discovery market in South America?

Factors likely include advancements in technology, increasing investment from key players, and a growing focus on therapeutic applications. Read More

South America Antibody Drug Discovery Market

ID: MRFR/MED/50169-HCR

200 Pages

Nidhi Mandole

Last Updated: April 02, 2026

South America Antibody Drug Discovery Market Research Report: Size, Share, Trend Analysis By Types (Monoclonal Antibodies, Polyclonal Antibodies, Antibody-Drug Conjugates, Bispecific Antibodies), By Technology (Recombinant DNA Technology, Hybridoma Technology, Phage Display Technology, Transgenic Technology), By Applications (Therapeutic Applications, Diagnostic Applications, Research Applications), By End Use (Pharmaceutical Companies, Biotechnology Companies, Research Institutions) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035

South America Antibody Drug Discovery Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Security, Access Control and Robotics, BY Type (USD Million) | |
  1. 4.1.1 Monoclonal Antibodies | |
  2. 4.1.2 Polyclonal Antibodies | |
  3. 4.1.3 Antibody-Drug Conjugates | |
  4. 4.1.4 Bispecific Antibodies |
2. 4.2 Security, Access Control and Robotics, BY Technology (USD Million) | |
  1. 4.2.1 Recombinant DNA Technology | |
  2. 4.2.2 Hybridoma Technology | |
  3. 4.2.3 Phage Display Technology | |
  4. 4.2.4 Transgenic Technology |
3. 4.3 Security, Access Control and Robotics, BY Application (USD Million) | |
  1. 4.3.1 Therapeutic Applications | |
  2. 4.3.2 Diagnostic Applications | |
  3. 4.3.3 Research Applications |
4. 4.4 Security, Access Control and Robotics, BY End Use (USD Million) | |
  1. 4.4.1 Pharmaceutical Companies | |
  2. 4.4.2 Biotechnology Companies | |
  3. 4.4.3 Research Institutions 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Roche (CH) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 AbbVie (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Amgen (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Johnson & Johnson (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Merck & Co. (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Novartis (CH) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Bristol-Myers Squibb (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GSK (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Sanofi (FR) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 SOUTH AMERICA MARKET ANALYSIS BY TYPE |
6. 6.3 SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
7. 6.4 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
8. 6.5 SOUTH AMERICA MARKET ANALYSIS BY END USE |
9. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS |
12. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS |
14. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS |
15. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE) |
16. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million) |
17. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TECHNOLOGY, 2024 (% SHARE) |
18. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TECHNOLOGY, 2024 TO 2035 (USD Million) |
19. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 (% SHARE) |
20. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 TO 2035 (USD Million) |
21. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USE, 2024 (% SHARE) |
22. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USE, 2024 TO 2035 (USD Million) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
  2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Million) | |
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million) | |
  4. 7.2.4 BY END USE, 2025-2035 (USD Million) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

South America Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Type (USD Million, 2025-2035)

Monoclonal Antibodies
Polyclonal Antibodies
Antibody-Drug Conjugates
Bispecific Antibodies

Security, Access Control and Robotics By Technology (USD Million, 2025-2035)

Recombinant DNA Technology
Hybridoma Technology
Phage Display Technology
Transgenic Technology

Security, Access Control and Robotics By Application (USD Million, 2025-2035)

Therapeutic Applications
Diagnostic Applications
Research Applications

Security, Access Control and Robotics By End Use (USD Million, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓